CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving the use of doxorubicin, a key chemotherapy drug for childhood cancers, by studying its pharmacokinetics and metabolism in young patients. By collaborating with various experts, the project aims to generate high-quality data to optimize treatment and minimize toxicities in children.
Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers.
Nevertheless, at least 20% of patients are not cured by current therapies and a significant number experience debilitating toxicities.
Given the high cure rates and potential life-span of survivors of childhood cancer, it is particularly important to minimize the impact of potential chronic toxicities.
For several of the most widely-used drugs, little is known about their pharmacokinetics and metabol…
UNIVERSITY OF NEWCASTLE UPON TYNE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Leicester
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, NEWCASTLE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 sectors.
